Europe faces a sharp rise in hepatitis A cases, with over 2,000 infections in 2025. Vulnerable groups are most affected as ECDC urges vaccination and sanitation efforts.

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Chronic hepatitis C is a growing health problem worldwide that has attracted increased attention in recent years. Treatment with peginterferon and ribavirin combination had previously been the ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

Hepatitis A outbreak strikes elite enclave known as playground for the rich. ... There is no treatment for the condition other than antibody therapy and vaccines within two weeks of exposure. ...

Hepatitis A, a virus affecting the liver, is considered a serious hazard as it causes “incapacitating” illness for a moderate duration which, in rare cases, can be life threatening.

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Hepatitis A virus (HAV) is the most common cause of infectious hepatitis throughout the world with more than 1.5 million clinical cases reported annually. However, ...

Among herbal ingredients tied to toxic hepatitis, turmeric is the most commonly consumed in the U.S., according to a study published last year in the journal JAMA Network Open.

Cuts to federal research funding may delay a potential hepatitis B cure, as trials led by UCSF progress. Asian Americans ...

Drug Farm and Xiamen Amoytop Biotech Co., Ltd. Enter into Option Agreement for First-In-Class Innate Immunity Agonist, DF-006 to Treat Hepatitis B and Hepatocellular Cancer ...